Did Sharon Osbourne confirm which specific GLP-1 drug she used?

Yes. In her 2023 TalkTV appearances and subsequent interviews, Osbourne specifically named Ozempic (semaglutide). She did not mention Wegovy, Mounjaro, or any other GLP-1 receptor agonist.

How much weight did Sharon Osbourne say she lost on Ozempic?

Osbourne stated publicly that she lost approximately 30 pounds and described the result as excessive for her frame. She used the words "too much" and "frightening" in televised interviews.

Is losing too much weight a recognized side effect of Ozempic?

Excessive weight loss is not listed as a named adverse event in the Ozempic label, but the Wegovy label (same molecule, higher dose) instructs providers to monitor for it. Clinical trials show significant variability in weight loss response, with some patients losing substantially more than the population mean.

Are older adults at higher risk for side effects from GLP-1 medications?

Yes. Adults over 65 face amplified risk of lean mass (muscle) loss during pharmacological weight reduction. Age-related sarcopenia means they start with less muscle reserve, and GLP-1-induced weight loss draws disproportionately from lean tissue. The FDA label recommends caution in geriatric patients.

Did Sharon Osbourne stop taking Ozempic?

Yes. Osbourne confirmed in 2023 that she discontinued Ozempic due to excessive weight loss and expressed interest in regaining some of the lost weight.

Side Effects Sharon Osbourne Publicly Discussed (and What They Match in the Clinical Literature)

By HealthRX.com Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

Clinical image for Side Effects Sharon Osbourne Publicly Discussed (and What They Match in the Clinical Literature) Image: HealthRX.com clinical image

What Sharon Osbourne Said Publicly

In a series of interviews throughout 2023, Sharon Osbourne confirmed she had used Ozempic (semaglutide 0.5 mg, 1 mg, or 2 mg weekly injection, approved for type 2 diabetes but widely prescribed off-label for weight management). Speaking on Piers Morgan's TalkTV program and in subsequent press appearances, Osbourne stated she had dropped approximately 30 pounds and felt the loss was excessive for her frame.

She described looking "gaunt," said she could not stop the weight from coming off while on the drug, and used the word "frightening" to characterize her experience. By mid-2023 she confirmed discontinuing Ozempic and expressed a desire to regain some of the lost weight.

These are first-person, on-camera disclosures. Nothing in this article relies on speculation about her private medical decisions.

At a glance

Drug confirmed: Ozempic (semaglutide), a GLP-1 receptor agonist
Status: Confirmed use and confirmed discontinuation (2023)
Primary complaint: Excessive, unintended weight loss
Clinical match: Documented adverse event profile in adults over 65
Relevance: Illustrates under-discussed risk of lean mass loss in older GLP-1 users

The Side Effect She Described: Excessive Weight Loss

Osbourne's central complaint was not nausea, not injection site reactions, not the gastrointestinal symptoms that dominate GLP-1 media coverage. It was that the drug worked too well for weight reduction, past the point she considered healthy or desirable.

This may sound paradoxical for a weight-loss medication. It is not. The FDA label for semaglutide 2.4 mg (Wegovy) reports mean weight loss of 14.9% of body weight at 68 weeks in the STEP 1 trial (Wilding et al., NEJM 2021). Some participants lost considerably more. The distribution has a long tail on the high-response end, and individual pharmacokinetics, starting weight, caloric intake, and age all influence magnitude.

For a woman in her early 70s at the time of use, 30 pounds represents a physiologically different event than it does for a 40-year-old with 80 pounds to lose. The clinical literature treats these populations differently for good reason.

Clinical Context: Why Older Adults Face Amplified Risk

Sarcopenia and the Composition Problem

Weight loss in adults over 65 carries a specific hazard: a disproportionate fraction of the lost mass comes from skeletal muscle rather than adipose tissue. This phenomenon, well-characterized in the bariatric surgery literature, applies equally to pharmacological weight loss.

A 2021 sub-analysis of the STEP 3 trial showed that approximately 39% of total weight lost on semaglutide was lean body mass (Wilding et al., NEJM 2021). In older adults already experiencing age-related sarcopenia, this ratio raises the risk of frailty, falls, and functional decline.

The STEP 2 trial population (type 2 diabetes, mean age ~55) demonstrated similar body composition shifts (Davies et al., Lancet 2021). Extrapolating to a 70-year-old with lower baseline muscle mass, the HealthRX.com Medical Team notes the clinical concern is not theoretical.

Appetite Suppression Without a Floor

GLP-1 receptor agonists reduce appetite through central mechanisms (hypothalamic signaling, delayed gastric emptying, and altered reward pathways). In some patients, this suppression is profound enough that caloric intake drops well below maintenance without triggering compensatory hunger signals.

Osbourne's description of being unable to stop the weight loss while on the drug is consistent with this pharmacology. Semaglutide's half-life is approximately 7 days, meaning drug effect persists long after a given injection. Dose reduction or discontinuation is the primary intervention when weight loss overshoots the target.

The FDA Label Acknowledges This

The Ozempic prescribing information lists "decreased appetite" as a very common adverse reaction (reported in 6-11% across dose groups in registration trials). The Wegovy label goes further, noting that patients should be monitored for nutritional deficiencies and excessive weight loss.

Section 5.8 of the Wegovy label explicitly warns about the potential for suicidal ideation, but notably, there is no black-box warning about excessive weight loss per se. The HealthRX.com Medical Team considers this a gap. Clinical practice guidelines from the Endocrine Society recommend regular body composition assessment during pharmacological weight management, particularly in older adults, but this guidance often does not reach the prescribing moment.

Other Side Effects in the Semaglutide Profile

While Osbourne's public statements focused on excess weight loss, the documented adverse event profile of semaglutide includes several categories worth noting for context:

Gastrointestinal (most common): Nausea (reported in 15-44% depending on dose and formulation), vomiting (5-24%), diarrhea (8-30%), constipation (5-24%), abdominal pain. These are dose-dependent and typically attenuate over 4-8 weeks (Marso et al., NEJM 2016).

Metabolic: Hypoglycemia (primarily when combined with sulfonylureas or insulin), fatigue, dizziness.

Pancreatitis: Rare but documented. The FDA label carries a warning. Incidence in trials was <1% but statistically above placebo.

Gallbladder events: Cholelithiasis occurs at higher rates during rapid weight loss on GLP-1 agonists. The STEP trials reported gallbladder-related events in 1.6% of semaglutide patients vs. 0.7% placebo.

Thyroid C-cell tumors: Observed in rodents. The FDA label carries a boxed warning. Clinical relevance in humans remains uncertain, but semaglutide is contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2.

Osbourne has not publicly discussed experiencing any of these additional effects. We do not speculate about symptoms she has not disclosed.

The HealthRX.com Medical Team Take

Sharon Osbourne's public experience represents one of the clearest celebrity-documented cases of GLP-1 overshoot, where the drug's efficacy becomes the adverse event.

Three clinical points deserve emphasis:

1. Age changes the risk calculus. A 70-year-old woman losing 30 pounds on semaglutide is not pharmacologically equivalent to a 45-year-old losing the same amount. Baseline lean mass, bone density, and recovery capacity differ. Prescribers should consider lower starting doses and more frequent monitoring in patients over 65 (FDA Ozempic Label, Section 8.5).

2. The "can't stop losing" phenomenon is real. Semaglutide's long half-life means effects persist 2-5 weeks after discontinuation. Patients who overshoot cannot simply "eat more" against active GLP-1 receptor agonism. Osbourne's decision to discontinue was, from a clinical perspective, appropriate.

3. Body composition monitoring is not optional. DEXA or bioimpedance assessment at baseline and every 3-6 months during GLP-1 therapy should be standard of care, particularly in older patients. Without it, clinically significant muscle loss can proceed undetected until functional consequences emerge.

Osbourne's willingness to discuss these effects publicly provides a useful counterpoint to the prevailing narrative that GLP-1 medications are universally safe at any age or starting weight. They are effective. They are also potent. Those two qualities demand proportionate clinical oversight.

Frequently asked questions

›

References

Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00213-0/fulltext
Marso SP, Daniels GH, Tanaka K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-322. https://www.nejm.org/doi/full/10.1056/NEJMoa1607141
FDA. Ozempic (semaglutide) Prescribing Information. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209637s009lbl.pdf
FDA. Wegovy (semaglutide) Prescribing Information. 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf
Endocrine Society. Pharmacological Management of Obesity Clinical Practice Guideline. https://www.endocrine.org/clinical-practice-guidelines/obesity